GET DAILY SIGNALSPfizer (PFE, $42.31) Declares Closure of Two Major India Plants
US pharmaceutical giant, Pfizer, has recently confirmed the closure of its two Hospira manufacturing plant sites in India, one at Aurangabad (Maharashtra) and the other at Irungattukottai (Tamil Nadu). The IKKT and Aurangabad plants employ around 1,000 and 700 people, respectively. This decision has jeopardized those jobs and no compensation has been discussed so far.
The decision to close down these two plants was reached after a thorough evaluation that revealed long-term irrevocable losses making manufacturing unfeasible at these sites.
The IKKT plant used to manufacture generic injectable cephalosporin, penems and penicillin for the US, EU and other global markets. It also produced branded Maxipime. Aurangabad, on the other hand, supports IKKT by supplying penems and penicillin. Until recently, both sites also provided products to Orchid Pharmaceuticals. Neither plant makes products for domestic use in India.
The final blow to the company’s manufacturing came when the USFDA issued a warning letter in 2013, particularly addressing the IKKT plant.
However, on a positive note, the company’s other manufacturing facilities in Goa and Vishakhapatnam, along with its joint venture site in Ahmedabad, will remain operational and the company plans to further expand its operations in these sites.
PFE's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for PFE turned positive on October 14, 2026. Looking at past instances where PFE's MACD turned positive, the stock continued to rise in 23 of 42 cases over the following month. The odds of a continued upward trend are 55%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on PFE as a result. In 43 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 49%.
Following a +2.40% 3-day Advance, the price is estimated to grow further. Considering data from situations where PFE advanced for three days, in 152 of 281 cases, the price rose further within the following month. The odds of a continued upward trend are 54%.
The Aroon Indicator entered an Uptrend today. In 87 of 196 cases where PFE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 44%.
Bearish Trend Analysis
The 10-day RSI Indicator for PFE moved out of overbought territory on October 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In 15 of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at 56%.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PFE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 3 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 20 (best 1 - 100 worst), indicating outstanding price growth. PFE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 83 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 96 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.052) is normal, around the industry mean (-1.476). P/E Ratio (39.831) is within average values for comparable stocks, (21.871). Projected Growth (PEG Ratio) (13.137) is also within normal values, averaging (5.738). Dividend Yield (0.056) settles around the average of (0.038) among similar stocks. P/S Ratio (2.469) is also within normal values, averaging (4.033).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PFE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 60, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of vaccines and injectable biologic medicines
Industry PharmaceuticalsMajor
Advertisement